On September 9, 2026, shareholders of iTonic Holdings Ltd approved a reverse stock split consolidating every sixteen existing Class A and Class B ordinary shares into one new share. The consolidation is effective October 6, 2026, subject to Nasdaq notification requirements. Concurrently, the company increased its authorized share capital from US$50,000 (divided into 400 million Class A and 100 million Class B shares) to US$800,000 (divided into 400 million Class A and 100 million Class B shares). The company also adopted a fourth amended and restated memorandum and articles of association to reflect these changes. iTonic Holdings Ltd operates in the technology sector.

iTonic Holdings Ltd announced an extraordinary general meeting for September 9, 2026, to vote on a proposed 1-for-16 reverse stock split effective October 6, 2026, subject to Nasdaq approval. The consolidation reduces the authorized share capital from US$50,000 divided into 400 million Class A and 100 million Class B shares to US$50,000 divided into 25 million Class A and 6.25 million Class B shares. Shareholders will also vote to increase authorized share capital to US$800,000 divided into 400 million Class A and 100 million Class B shares and adopt a fourth amended memorandum and articles of association. The company operates in the technology industry.

On June 18, 2026, Bin Wu resigned as an independent director for personal reasons, stating no disagreement with company operations or policies. Simultaneously, the board appointed Kun Yang as an independent director and member of the Audit, Compensation, and Corporate Governance and Nominating committees. Kun Yang also assumed the role of chair of the Corporate Governance and Nominating Committee. iTonic Holdings Ltd operates in the healthcare industry, providing medical devices and solutions.